Gland Pharma Holds Near Highs Despite Fosun Stake Sale

Gland Pharma gained 0.84% on September 4 despite a major Fosun stake sale, with the stock trading close to its 52-week high. Gland Pharma Ltd. (NSE:

) remained resilient on September 4, 2026, closing 0.84% higher despite significant promoter stake-sale activity. The stock ended the session just 3.53% below its 52-week and nearly three-year high of ₹3,039.80, reflecting continued investor interest. In pre-open market activity, Fosun Pharma Industrial was reportedly looking to sell around 5% of its stake in Gland Pharma through a block deal valued at approximately ₹2,279.5 crore. The reported floor price for the transaction was ₹2,763 per share. Subsequent reports indicated that Fosun Pharma ultimately sold a 4.5% stake for around ₹2,121.5 crore. The shares were reportedly acquired by 11 institutional investors at a price of ₹2,826.60 per share, highlighting strong institutional demand despite the large transaction size. The stake sale marks a notable change in the company's ownership structure and is expected to improve the stock's free float. Market participants will closely monitor whether the entry of institutional investors supports liquidity and sustains the stock's upward momentum. With Gland Pharma trading near its recent highs, future earnings performance and business developments are likely to remain key factors influencing investor sentiment. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.